Damora Therapeutics, Inc. (DMRA) UBS Global Biopharma Conference 2026 November 17, 2026 5:00 AM EST.
Jennifer Jarrett - CEO, President & DirectorSherwin Sattarzadeh - Chief Operating Officer.
Matthew Hagood - UBS Investment Bank, Research Division.
Matthew HagoodUBS Investment Bank, Research Division.
In a recent development, all right. Well, great. Thank you, guys, for being here. We're going to get started with our next session. My name is Matt Hagood. I'm on the research team here at UBS working with Mike Yee. We are excited to welcome our next presenting organization, Damora Therapeutics, and we have the team here. Guys, thanks for being here.
Matthew HagoodUBS Investment Bank, Research Division.
Maybe give a quick introduction and then some background on Damora and the progress you made this year and kind of the mCALR space that you're working in. It would be great.
Jennifer JarrettCEO, President & Director.
Yes. So just quickly for introductions. I'm Jen Jarrett and I'm the CEO of Damora.
Sherwin SattarzadehChief Operating Officer.
I'm Sherwin Sattarzadeh, the Chief Operating Officer.
Jennifer JarrettCEO, President & Director.
So background on Damora. So we are a Fairmount firm. We're actually the sixth company that was founded by Fairmount. I'm sure you guys are familiar with a lot of the other Fairmount companies, I think they're up to like 11 or 12 and definitely double digits now. We were founded specifically to focus on hematological diseases and our initial focus is on the myeloproliferative neoplasm space. So myeloproliferative neoplasm is a group of blood cancers.
The 2 that we are focusing on is: essential thrombocythemia, which is when a patient produces too many platelets; and myelofibrosis, which is when a patient cannot produce healthy blood cells and so these patients tend to be either anemic or.
